Doripenem: antimicrobial profile and clinical potential

Diagnostic Microbiology and Infectious Disease

Volumn 63, Issue 4, 2009, Pages 455-458

  Livermore, David M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Carbapenemase; Carbapenems; Doripenem; Meropenem

Indexed keywords

DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG SENSITIVITY; ENTEROBACTERIACEAE; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

BACTERIA; BACTERIAL INFECTIONS; CARBAPENEMS; HUMANS;

EID: 62249093063     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.02.012     Document Type: Article

References (27)

1. VIM-1) genes in multiple species of Enterobacteriaceae from Bolzano, Italy. J. Antimicrob. Chemother. 61 (2008) 515-523
2. Calandra G., Ricci F., Wang C., and Brown K. Cross-resistance and imipenem. Lancet 2 (1986) 340-341
3. Carmeli Y., Troillet N., Eliopoulos G.M., and Samore M.H. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43 (1999) 1379-1382
4. Carrer A., Poirel L., Eraksoy H., Cagatay A.A., Badur S., and Nordmann P. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob. Agents Chemother. 52 (2008) 2950-2954
5. Castanheira M., Jones R.N., and Livermore D.M. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn. Microbiol. Infect. Dis. 63 (2009) 426-433
6. Fritsche T.R., Sader H.S., Stilwell M.G., and Jones R.N. Antimicrobial activity of doripenem tested against prevalent gram-positive pathogens: results from a global surveillance study (2003-2007). Diagn. Microbiol. Infect. Dis. 63 (2009) 440-446
7. Goldstein E.P., and Citron D.M. Activity of a novel carbapenem doripenem against anaerobic pathogens. Diagn. Microbiol. Infect. Dis. 63 (2009) 447-454
8. Hawkey P.M. Prevalence and locality of extended-spectrum β-lactamases in Asia. Clin. Microbiol. Infect. 14 Suppl 1 (2008) 159-165
9. Hikida M., Itahashi K., Igarashi A., Shiba T., and Kitamura M. In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity. Antimicrob Agents Chemother 43 (1999) 2010-2016
10. Horiuchi M., Kimura M., Tokumura M., Hasebe N., Arai T., and Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 222 (2006) 114-124
11. Jones R.N., Bell J.M., Sader H.S., Turnidge J., and Stilwell M.G. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens. Diagn. Microbiol. Infect. Dis. 63 (2009) 434-439
12. Lewis J.S., Herrera M., Wicke B., Patterson J.E., and Jorgensen J.H. First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a US health care system. Antimicrob. Agents Chemother. 51 (2007) 4015-4021
13. Livermore D.M., Canton R., Gniadkowski M., et al. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 59 (2007) 165-174
14. Livermore D.M., and Warner M. Effects of low temperature and high salt on the activity of the novel carbapenem PZ-601 (SMP-601) against meticillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 63 (2009) 411-413
15. Lomaestro B.M., and Drusano G.L. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob. Agents Chemother. 49 (2005) 461-463
16. Mendes R.E., Rhomberg P.R., Turnidge J., and Sader H.S. Doripenem activity against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. Diagn. Microbiol. Infect. Dis. 63 (2009) 415-425
17. Mori M., Hikida M., Nishihara T., Nasu T., and Mitsuhashi S. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J. Antimicrob. Chemother. 37 (1996) 1034-1036
18. Mushtaq S., Ge Y., and Livermore D.M. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 48 (2004) 3086-3092
19. Poirel L., Pitout J.D., and Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol. 2 (2007) 501-512
20. Sakyo S., Tomita H., Tanimoto K., Fujimoto S., and Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J. Antibiot. (Tokyo) 59 (2006) 220-228
21. Schwaber M.J., and Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother. 60 (2007) 913-920
22. Soo Hoo G.W., Wen Y.E., Nguyen T.V., and Goetz M.B. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 128 (2005) 2778-2787
23. Van Wart S.V., Andes D.R., Ambrose P.G., and Bhavnani S.M. Pharmacokinetic-pharmacodynamic modelling to support doripenem dose regimen optimization for critically ill patients. Diagn. Microbiol. Infect. Dis. 63 (2009) 409-414
24. Vatopoulos A. High rates of metallo-β-lactamase-producing Klebsiella pneumoniae in Greece-a review of the current evidence. Eurosurv (2008) 13
25. Villegas M.V., Kattan J.N., Quinteros M.G., and Casellas J.M. Prevalence of extended-spectrum β-lactamases in South America. Clin. Microbiol. Infect. 14 Suppl 1 (2008) 154-158
26. Walsh T.R. Clinically significant carbapenemases: an update. Curr. Opin. Infect. Dis. 21 (2008) 367-371
27. Yan J.J., Ko W.C., Tsai S.H., Wu H.M., and Wu J.J. Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying bla(IMP-8) in a university medical center in Taiwan. J. Clin. Microbiol. 39 (2001) 4433-4439